Pytest

Urea, C-14


Avent, Inc.
Human Prescription Drug
NDC 42536-6046
Pytest also known as Urea, C-14 is a human prescription drug labeled by 'Avent, Inc.'. National Drug Code (NDC) number for Pytest is 42536-6046. This drug is available in dosage form of Capsule. The names of the active, medicinal ingredients in Pytest drug includes Urea C-14 - 1 uCi/1 . The currest status of Pytest drug is Active.

Drug Information:

Drug NDC: 42536-6046
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Pytest
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Urea, C-14
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Avent, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Capsule
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:UREA C-14 - 1 uCi/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 09 May, 1997
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 31 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA020617
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Avent, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:WBZ6M63TEE
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
42536-6046-11 BLISTER PACK in 1 PACKAGE, COMBINATION (42536-6046-1) / 1 CAPSULE in 1 BLISTER PACK09 May, 1997N/ANo
42536-6046-210 CAPSULE in 1 PACKAGE, COMBINATION (42536-6046-2)09 May, 1997N/ANo
42536-6046-3100 CAPSULE in 1 PACKAGE, COMBINATION (42536-6046-3)09 May, 1997N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Pytest urea, c-14 urea c-14 urea c-14 light lemon yellow oval

Drug Interactions:

Drug interactions antibiotics, proton pump inhibitors, sucralfate, and bismuth preparations are known to suppress h.pylori. ingestion of antibiotics or bismuth within 4 weeks and proton pump inhibitors or sucralfate within 2 weeks prior to performing the test may give false negative results.

Indications and Usage:

Indications and usage pytest ( 14 c-urea breath test) is indicated for use in the detection of gastric urease as an aid in the diagnosis of h.pylori infection in the human stomach. the test utilizes a liquid scintillation counter for the measurement of 14 co 2 in breath samples.

Warnings:

Warnings none

General Precautions:

General after the patient ingests the 14 c-urea capsule, the sample collected for test purposes is for in vitro diagnostic use only. a false positive test could occur in patients who have achlorhydria. very rarely, a false positive test may occur due to urease associated with helicobacters other than h.pylori (i.e. helicobacter heilmanni ).

Dosage and Administration:

Dosage and administration materials provided as shown in figure 2, the pytest kit contains: pytest capsule two 30 ml disposable cups one drinking straw one mylar collection balloon one report form one mailing box with labels the kit includes analysis by kimberly-clark of one balloon from one patient at one time point. figure 2: pytest kit materials needed but not provided stopwatch/timer capable of timing an interval up to 10 minutes. water (40ml) dosage one pytest capsule. procedural notes inform the patient to fast for 6 hours prior to the test. the patient should be off antibiotics and bismuth for 1 month, and proton pump inhibitors and sucralfate for 2 weeks prior to the test. have patient sitting at rest while doing the test. the capsule should not be handled directly as this may interfere with the test result. to avoid contamination by bacteria in the mouth, the capsule should be swallowed intact. do not chew capsule. step by step procedure for balloon table 3: breath sample coll
ection by balloon before the test label balloon and fill in breath test report form. check that all materials are present. minus 1 open the package containing the 14 c-urea capsule minute and tip the capsule into the empty 30 ml cup. do not handle the capsule directly. hand the cup to the patient. fill the second cup with 20 ml lukewarm water. 0 minute ask the patient to tip the capsule directly into his/her mouth, then swallow it with the 20 ml of lukewarm water. start the stopwatch when the patient swallows the capsule. discard waste (e.g., capsule packaging, used straws) according to your facility's regulations. 3 minutes ask the patient to drink another 20 ml of lukewarm water (in case the capsule may have lodged in the esophagus and not yet reached the gastric mucosa). 10 minutes push a drinking straw into the neck of the balloon. ask the patient to hold his/her breath for 5-10 seconds, then blow up a balloon with a slow breath through the straw, filling the balloon completely. tie the neck of the balloon into a tight knot. check that the balloon label and the breath test report form are completed correctly. after the test place the filled balloon and breath test report in the box and forward to kimberly-clark for analysis. quality control a minimum of 1 mm of co 2 is required to perform analysis of a breath sample. the amount of breath required to provide 1 mm of co 2 varies depending on the amount of co 2 the patient is producing. since a full balloon typically contains at least 1 mm of co 2 , the balloon should be completely filled. results interpretation of results (10 minute sample) <50 dpm negative for h.pylori 50-199 dpm indeterminate for h.pylori ≥200 dpm positive for h.pylori the indeterminate result should be evaluated by repeating the pytest or using an alternative diagnostic method. if repeat breath testing is undertaken, careful history to exclude confounding factors should be obtained. if confounding factors are present, wait an appropriate time (refer to table 4 ) before repeating the pytest . the cutoff point of 50 dpm was determined to be the mean + 3sd of results obtained in patients who did not have h.pylori . dpm = disintegrations per minute table 4: factors which might cause sub-optimal breath test results factor result comment recent antibiotic or bismuth (pepto-bismol, etc.) false neg. relapse of partially treated hp may take 1-4 weeks. omeprazole (or other proton pump inhibitors) false neg. these agents suppress hp in 40% of patients. discontinue for at least 2 weeks before performing the pytest . resective gastric surgery false neg. isotope may empty rapidly from the stomach. resective gastric surgery false pos. patient may be achlorhydric and have bacterial overgrowth (non- hp urease). food in stomach (also bezoar, gastroparesis) unknown isotope may not come into contact with gastric mucosa. patient may be achlorhydric and/or have bacterial overgrowth (non- hp urease). expected values as shown in figure 3 approximately 30% of patients tested will be positive for h.pylori . figure 3: histogram showing dpm distribution for the pytest . note: dpm groupings were calculated on a logarithmic scale. empty dpm groupings were not included. chart includes all patients from studies 1 and 2. frequency of dpm group includes samples with dpm < group name. dpm = disintegrations per minute gold standard = agreement between histology and clotest if the capsule is damaged or appears abnormal in any way, it may give inaccurate results.

Contraindications:

Contraindications none

Adverse Reactions:

Adverse reactions no adverse reactions were reported in clinical trials.

Drug Interactions:

Drug interactions antibiotics, proton pump inhibitors, sucralfate, and bismuth preparations are known to suppress h.pylori. ingestion of antibiotics or bismuth within 4 weeks and proton pump inhibitors or sucralfate within 2 weeks prior to performing the test may give false negative results.

Use in Pregnancy:

Pregnancy pregnancy category c animal reproduction studies have not been conducted with pytest ( 14 c-urea). it is also not known whether pytest can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. pytest should be given to a pregnant woman only if clearly needed.

Pediatric Use:

Pediatric use clinical studies in children have not been conducted. however, pytest is expected to work the same in children as in adults. while the dose (1 capsule) does not need to be adjusted, the child must be able to swallow the intact capsule and blow into a straw.

Overdosage:

Overdosage risk from radiation is negligible even with a 1000 capsule overdose (0.3 rem). if overdose occurs, the patient may drink one glass of water (150 ml) every hour to hasten excretion of the isotope. maximum excretion of urea is achieved at a urine output of ≥2.0 ml/min.

Description:

Description pytest registered trademark or trademark of kimberly-clark worldwide, inc. ( 14 c-urea breath test) is a qualitative and non-invasive method for the diagnosis of helicobacter pylori (h.pylori) . to detect h.pylori, 14 c-urea supplied in a capsule is swallowed by the patient. if gastric urease from h.pylori is present, urea is split to form co 2 and nh 3 . ten minutes after the patient ingests the capsule, a breath sample is collected into a balloon. the breath sample is later transferred to collection fluid to trap the labeled co 2 . the liquid sample is then analyzed in a liquid scintillation counter. the pytest kit ( 14 c-urea breath test) is designed for use with the pytest capsule, a gelatin capsule for oral administration containing 1 µci of 14 c labeled urea. the urea is adsorbed on sugar spheres and colored yellow with fluorescein. data on 14 c-urea structural formula ( 14 c-urea): nh 2 14 conh 2 radiation emission: beta-emission, 49 kev mean, 156 kev max, no other emissions external emission: no external radiation hazard. low-energy beta emissions only. maximum range of 0.3 mm in water. radiological half-life: 5730 years maximum effective dose equivalent (ede) : 0.3 mrem/µci figure 1 figure 2 figure 3

Clinical Pharmacology:

Clinical pharmacology the urease enzyme is not present in mammalian cells, so the presence of urease in the stomach is evidence that bacteria are present. the presence of urease is not specific for h.pylori , but other bacteria are not usually found in the stomach. the principle of the breath test is shown in figure 1. figure 1: principle of breath test to detect h.pylori , urea labeled with 14 c is swallowed by the patient. if gastric urease from h.pylori is present, urea is split to form co 2 and nh 3 at the interface between the gastric epithelium and lumen and 14 co 2 is absorbed into the blood and exhaled in the breath. following ingestion of the capsule by a patient with h.pylori , 14 co 2 excretion in the breath peaks between 10 and 15 minutes and declines thereafter with a biological half-life of about 15 minutes. 14 c-urea that is not hydrolyzed by h.pylori is excreted in the urine with a half-life of approximately 12 hours. about 10% of the 14 c remains in the body at 72 hour
s and is gradually excreted with a biological half-life of 40 days.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility no studies have been conducted with 14 c-urea to evaluate its potential for carcinogenicity, impairment of fertility, or mutagenicity.

Clinical Studies:

Clinical studies two studies were performed. in both studies, patients with gastrointestinal symptoms underwent the breath test and an endoscopy. during the endoscopy, biopsy samples were taken from the antral gastric mucosa for histological analysis (2 samples, giemsa stain) and rapid urease test (1 sample, clotest ). breath samples were mailed to the tri-med lab where they were read in a liquid scintillation counter. results were reported as disintegrations per minute (dpm). analysis for accuracy used the ten minute breath sample. a breath sample dpm <50 was defined as a negative result. dpm ≥200 was defined as a positive result. dpm in the range of 50 -199 was classified as indeterminate. study 1 of 186 patients who had histopathology and clotest (80 men, 106 women), 53 were infected with h.pylori as determined by agreement between histology and clotest . the study results are summarized below: table 1: study #1 (n=186, indeterminate results included) histology and clotest h.py
lori positive negative total notes: pytest at 10 min. was compared to the gold standard of biopsy results in which histology and clotest concurred. patients who did not have both biopsy tests performed, or in whom the tests differed, were excluded from analysis. there was no statistical difference in test accuracy based on gender of patient. ppv = positive predictive value (true positive divided by total pytest positive) npv = negative predictive value (true negative divided by total pytest negative) pytest positive 51 8 59 ppv. 86% (dpm indeterminate 1 8 9 10m.) negative 1 117 118 npv. 99% total 53 133 186 sensitivity 96% specificity 88% study 2 breath tests were performed on 436 outpatients attending gastroenterology practices at sites in the united states. seventy-six patients (40 men, 36 women) who had histology and clotest were evaluated. the results are summarized below: table 2: study #2 (n=76, indeterminate results included) histology and clotest h.pylori positive negative total notes: pytest at 10 min. was compared to the gold standard of biopsy results in which histology and clotest concurred. patients who did not have both biopsy tests performed, or in whom the tests differed, were excluded from analysis. there was no statistical difference in test accuracy based on gender of patient. ppv = positive predictive value (true positive divided by total pytest positive) npv = negative predictive value (true negative divided by total pytest negative) pytest positive 22 0 22 ppv. 100% (dpm indeterminate 4 2 6 10m.) negative 1 47 48 npv. 98% total 27 49 76 sensitivity 82% specificity 96%

How Supplied:

How supplied pytest kit ( 14 c-urea breath test) is supplied as a kit containing a pytest capsule, a clear gelatin capsule containing 1µci of 14 c-urea and breath collection equipment. pytest capsules are also supplied separately in unit dose packages of 1,10 and 100. the pytest capsule has a shelf life of two years. the expiration date is printed on the capsule label. pytest capsules and kit should be stored at 15°-30°c (59°-86°f) in an area designated by each individual institution's regulations. rx only

Information for Patients:

Information for patients it is necessary for the patient to fast for 6 hours before the test. the patient should also be off antibiotics and bismuth for 1 month, and proton pump inhibitors and sucralfate for 2 weeks prior to the test. instruct the patient not to handle the capsule directly as this may interfere with the test result. the capsule should be swallowed intact. do not chew the capsule.

Package Label Principal Display Panel:

Principal display panel - 1 capsule blister pack kit label avanos* pytest* kit 14 c-urea breath test for the detection of helicobacter pylori contents – 1 pytest* capsule each containing 1 µci 14 c-urea pytest* breath collection accessories 14 c-urea (5730 years1/2, 156 kev [max.] β-emission) for dosage information, please see package insert this package conforms to the conditions and limitations specified in 49 cfr 173.421 for radioactive material, excepted package-limited quantity of material, un 2910. for in vitro diagnostic use rx only store at 15°–30°c (59°– 86°f) distributed in the usa by avanos medical sales, llc, 5405 windward parkway, alpharetta, ga 30004 usa. in usa, 1-844-428-2667. www.avanos.com avanos medical, inc., 5405 windward parkway, alpharetta, ga 30004 usa. ec|rep avanos medical belgium bvba, leonardo da vincilaan 1, 1930 zaventem, belgium. sponsored in australia by tri-med distributors pty ltd, 11 southport street, west leederville, wa 6007, australia. (+61 4 1793 3012). *registered trademark or trademark of avanos medical, inc., or its affiliates. © 2018 avns. all rights reserved. 20-m1-025-01 / 70211178 shell is shown for placement only lot 000000000000000 use by yyyy-mm-dd (01)00000000000000 (240)000000000 (17)yymmdd (10)000000000000000 ref 60461 109269502 ndc 42536-6046-1 principal display panel - 1 capsule blister pack kit label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.